Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza

 Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza

Celltrion and Teva’s Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA’s Approval for HER2-Overexpressing Breast Cancer

Shots:

  • Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets following its approval in the EU and the US
  • The focus of the agreement is to diversify Celltrion’s biosimilar supply base and meet the increasing demands of the biosimilar market. In H1’19, the companies have submitted the product produced at Singapore facility for EMA approval and will continue their collaboration for FDA’s approval
  • Remsima is the world’s first biosimilar mAb, approved by the EMA in Sept’2013 & the US FDA in Apr’2016 for multiple autoimmune diseases including CD, UC, RA, AS, PsA & PsO

Click here to­ read full press release/ article | Ref: Lonza | Image: The Korea Herald

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post